CompletedPhase 2NCT02960997
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Studying Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stanford University
- Principal Investigator
- Joyce M Teng, MD, PhDStanford School of Medicine
- Intervention
- Sirolimus, 2%(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2016 – 2021
Study locations (1)
- Stanford University, Palo Alto, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02960997 on ClinicalTrials.govOther trials for Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06509984A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex GeneralizedCentre Hospitalier Universitaire de Nice
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06073132An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)TWi Biotechnology, Inc.
See all trials for Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form →